Effects of lymphadenectomy among women with stage IA endometrial cancer: a SEER database analysis

Papers of special note have been highlighted as: • of interest

References

• 1. Ferlay J . GLOBOCAN 2000. Cancer incidence, mortality and prevalence worldwide, version 1.0. IARC Cancerbase (2001). https://publications.iarc.fr/Databases/Iarc-Cancerbases
  Google Scholar
• 2. Black JD , English DP , Roque DM , Santin AD . Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer. Women’s Health 10(1), 45–57 (2014).
  Medline CASGoogle Scholar
• 3. Wright JD , Medel NIB , Sehouli J , Fujiwara K , Herzog TJ . Contemporary management of endometrial cancer. Lancet 379(9823), 1352–1360 (2012).
  MedlineGoogle Scholar
• 4. Abu-Rustum NR , Iasonos A , Zhou Q et al. Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma? Am. J. Obstet. Gynecol. 198(4), 457. e451–457. e456 (2008).
  Google Scholar
• 5. Cohn DE , Huh WK , Fowler JM , Straughn JM . Cost–effectiveness analysis of strategies for the surgical management of grade 1 endometrial adenocarcinoma. Obstet. Gynecol. 109(6), 1388–1395 (2007).
  MedlineGoogle Scholar
• 6. Chan JK , Cheung MK , Huh WK et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer 107(8), 1823–1830 (2006). • Based on SEER database, this study analyzed 12,333 patients – from 1988 to 2001 – who were diagnosed with endometrioid uterine cancer and underwent a surgical staging procedure including lymph node (pelvic, periaortic or both) assessment, and found that extent of lymph node resection improves the survival of women with intermediate/high-risk endometrioid uterine cancer.
  MedlineGoogle Scholar
• 7. Cragun JM , Havrilesky LJ , Calingaert B et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J. Clin. Oncol. 23(16), 3668–3675 (2005).
  MedlineGoogle Scholar
• 8. Chan JK , Wu H , Cheung MK et al. The outcomes of 27,063 women with unstaged endometrioid uterine cancer. Gynecol. Oncol. 106(2), 282–288 (2007).
  MedlineGoogle Scholar
• 9. Trimble EL , Kosary C , Park RC . Lymph node sampling and survival in endometrial cancer. Gynecol. Oncol. 71(3), 340–343 (1998).
  Medline CASGoogle Scholar
• 10. May K , Bryant A , Dickinson HO , Kehoe S , Morrison J . Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst. Rev. (1), CD007585 (2010).
  MedlineGoogle Scholar
• 11. Kitchener H , Swart A , Qian Q , Amos C , Parmar M . Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373(9658), 125–136 (2009). • This randomized controlled trial contains 1408 women with histologically proven endometrial carcinoma, after a median follow-up of 37 months (interquartile range: 24–58), 251 women died or had recurrent disease (107 standard surgery group, 144 lymphadenectomy group), with an HR of 1.35 (1.06–1.73; p = 0.017) in the favor of standard surgery and an absolute difference in 5-year recurrence-free survival of 6% (95% CI: 1–12). This trial shows no evidence of benefit in terms of overall or recurrence-free survival for pelvic lymphadenectomy in women with early endometrial cancer.
  Medline CASGoogle Scholar
• 12. Panici PB , Basile S , Maneschi F et al. Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J. Natl Cancer Inst. 100(23), 1707–1716 (2008).
  MedlineGoogle Scholar
• 13. Abu-Rustum NR . Sentinel lymph node mapping for endometrial cancer: a modern approach to surgical staging. J. Natl Compr. Canc. Netw. 12(2), 288–297 (2014).
  MedlineGoogle Scholar
• 14. National Cancer Institute. SEER program SEER*Stat database: incidence e SEER 18 regs research data þ Hurricane Katrina impacted Louisiana cases, Nov 2013 sub (1973–2011 varying) e linked to county attributes e total US, 1969–2012 counties, National Cancer Institute, DCCPS, surveillance research program, surveillance systems branch, released April 2014 (updated 5/7/2014), based on the November 2013 submission. (2014). www.seer.cancer.gov
  Google Scholar
• 15. Gaynor JJ , Feuer EJ , Tan CC et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J. Am. Stat. Assoc. 88(422), 400–409 (1993).
  Google Scholar
• 16. Creasman WT , Morrow CP , Bundy BN et al. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study. Cancer 60(S8), 2035–2041 (1987).
  Medline CASGoogle Scholar
• 17. Chi D , Barakat R , Palayekar M et al. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology. Int. J. Gynecol. Cancer 18(2), 269–273 (2008).
  Medline CASGoogle Scholar
• 18. Kilgore LC , Partridge EE , Alvarez RD et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol. Oncol. 56(1), 29–33 (1995).
  Medline CASGoogle Scholar
• 19. Fanning J . Long-term survival of intermediate risk endometrial cancer (stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy. Gynecol. Oncol. 82(2), 371–374 (2001).
  Medline CASGoogle Scholar
• 20. Lutman CV , Havrilesky LJ , Cragun JM et al. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol. Oncol. 102(1), 92–97 (2006).
  MedlineGoogle Scholar
• 21. Papadia A , Gasparri ML , Siegenthaler F et al. FIGO stage IIIC endometrial cancer identification among patients with complex atypical hyperplasia, grade 1 and 2 endometrioid endometrial cancer: laparoscopic indocyanine green sentinel lymph node mapping versus frozen section of the uterus, why get around the problem? J. Cancer Res. Clin. 143(3), 491–497 (2017). • In this retrospective analysis, after analyzing the data of 116 patients, researchers found that indocyanine green sentinel lymph node mapping reduces the number of unnecessary systematic lymphadenectomies.
  MedlineGoogle Scholar
• 22. Rossi EC , Kowalski LD , Scalici J et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol. 18(3), 384–392 (2017).
  MedlineGoogle Scholar
• 23. Zahl Eriksson AG , Ducie J , Ali N et al. Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion. Gynecol. Oncol. 140(3), 394–399 (2016).
  MedlineGoogle Scholar
• 24. Papadia A , Imboden S , Siegenthaler F et al. Laparoscopic indocyanine green sentinel lymph node mapping in endometrial cancer. Ann. Surg. Oncol. 23(7), 2206–2211 (2016). • This retrospective analysis of 95 endometrial cancer patients undergoing indocyanine green sentinel lymph node mapping ± pelvic and/or para-aortic lymphadenectomy, and found that laparoscopic indocyanine green sentinel lymph node mapping has excellent overall and bilateral detection rates and a low false-negative rate. Compared with lymphadenectomy, sentinel lymph node biopsy is associated with significantly lower estimated blood loss and shorter operative time.
  MedlineGoogle Scholar
• 25. ASTEC/EN.5 Study Group , Blake P , Swart AM et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN. 5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 373(9658), 137 (2009). • This trial included 905 women with intermediate-risk or high-risk early-stage disease, found that there was no evidence that overall survival with external beam radiotherapy was better than observation, hazard ratio 1.05 (95% CI: 0.75–1.48; p = 0.77), because of this, the researchers don’t recommend adjuvant external beam radiotherapy as part of routine treatment for women with intermediate-risk or high-risk early-stage endometrial cancer with the aim of improving survival.
  MedlineGoogle Scholar
• 26. Keys HM , Roberts JA , Brunetto VL et al. A Phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 92(3), 744–751 (2004).
  MedlineGoogle Scholar
• 27. Straughn JM Jr , Huh WK , Orr JW Jr et al. Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy. Gynecol. Oncol. 89(2), 295–300 (2003).
  MedlineGoogle Scholar
• 28. Susumu N , Sagae S , Udagawa Y et al. Randomized Phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate-and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol. Oncol. 108(1), 226–233 (2008).
  Medline CASGoogle Scholar
• 29. Maggi R , Lissoni A , Spina F et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br. J. Cancer 95(3), 266 (2006).
  Medline CASGoogle Scholar